Can a shorter, oral combo tame early HER2-Positive breast cancer?

NCT ID NCT04383275

First seen Aug 19, 2026 ยท Last updated Aug 19, 2026

Summary

This trial is testing whether combining the targeted drug trastuzumab with either oral chemotherapy or hormone therapy can effectively treat stage I HER2-positive breast cancer. The study includes women aged 18-70 with small, lymph-node-negative tumors, divided into two groups based on hormone receptor status. The goal is to see if this approach can keep the cancer from coming back while potentially offering a more convenient treatment option.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
trastuzumab combined with capecitabine or endocrine therapy
What this could lead to
If successful, this could offer a less intensive, oral-based treatment option for early-stage HER2-positive breast cancer, potentially reducing recurrence while maintaining quality of life.
What could go wrong
This is a phase II trial, so results are preliminary. The combination may not improve outcomes over standard care, and side effects like heart toxicity or gastrointestinal issues could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Breast cancer institute of Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.